ACAM FLU A

Drug Profile

ACAM FLU A

Alternative Names: ACAM-Flu-A; ACAM-FLU-A; Influenza A vaccine (ACAM Flu-A) - Sanofi; Recombinant M2e influenza-A vaccine (ACAM FLU-A) - sanofi pasteur

Latest Information Update: 22 Oct 2013

Price : $50

At a glance

  • Originator Acambis; VIB
  • Developer sanofi pasteur
  • Class Influenza A vaccines; Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus infections

Most Recent Events

  • 22 Oct 2013 No development reported - Preclinical for Influenza A virus infections (prevention) in USA (Parenteral)
  • 01 Oct 2009 Preclinical trials in Influenza A virus infections (prevention; in volunteers) in USA (Parenteral)
  • 18 Feb 2009 sanofi-aventis completes a phase I trial in healthy adults in USA (NCT00819013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top